In recent years, the Centers for Disease Control and Prevention, the Department of Homeland Security, and other authorities have flagged a record number of unauthorized shipments of biological materials. At the same time, global intelligence communities have identified numerous attempts to smuggle sensitive biological samples in efforts of industrial theft or espionage. 

“A small vial of genetically engineered cells can contain multiple millions of dollars’ worth of intellectual property and require several years of work to develop,” said Corey Wilson, a professor in Georgia Tech’s School of Chemical and Biomolecular Engineering (ChBE). “Accordingly, the protection of high-value engineered cell lines has become critically important to the biotechnology industry.”

Wilson and his research team have published their findings in Science Advances demonstrating the effectiveness of their new biological security technology, known as GeneLock™, in protecting high-value engineered cell lines.

GeneLock is a cybersecurity-inspired technology that protects valuable genetic material directly at the DNA level. To demonstrate its strength, Wilson’s team conducted what they describe as a first-of-its-kind biohackathon, detailed in the new paper, to simulate unauthorized access. 

“GeneLock greatly improves our ability to protect high-value engineered cell lines by expanding security from the lab environment to the genetic level,” Wilson said.

Economic Impact

What are the stakes? Estimates place the global market for high-value genetic materials at more than $1.5 trillion, projected to reach $8 trillion by 2035. The use of these materials ranges from advanced medicines and proprietary research enzymes to specialty chemicals and sustainable materials.

Currently, the protection of high-value cell lines depends on physical safeguards such as restricted lab access and secure facilities, Wilson explained.

“The key weakness of physical security measures is once circumvented, there are typically no measures in place to protect valuable cells from theft, abuse, or unauthorized use,” Wilson said. 

“Once a sample leaves the building, the DNA it carries typically remains fully functional. This is akin to placing an unlocked cellphone in a desk drawer. Anyone who gains access to the drawer can view sensitive content on the phone­­­­­­­—or in this case will have full access to the valuable cell line.”

Genetic Passcode Protection

The GeneLock biological security technology developed by Wilson and his team places a passcode on engineered cells, akin to those used on ATM machines and protected cellphones.

Instead of leaving a valuable gene in readable form, the team scrambles the DNA sequence of interest. The scrambled genetic asset remains in a nonfunctional state unless the living cell where it resides receives the correct sequence of chemical inputs. Those inputs act as a molecular passcode.

“Only the right combination, delivered in the right order, rearranges the DNA into a working form,” Wilson said.

Biohackathon Security Test

To evaluate the technology, the researchers organized a blue team and a red team in what they describe as an ethical biohackathon. The blue team designed the encrypted DNA sequence, while the red team was challenged to discover the correct chemical passcode through experimentation in a gray box exercise, meaning the red team had partial knowledge of the system but did not have access to the internal designs. 

“This approach for testing security strength is commonly used in cybersecurity,” Wilson explained. 

The blue team engineered the system inside Escherichia coli, or E. coli, a bacterium widely used in biotechnology. The protected asset was a fluorescent protein gene selected as a measurable stand-in for commercially valuable targets. When the correct chemical sequence was applied, the fluorescence turned on. Without the correct passcode, the gene remained scrambled and the cells could not fluoresce green. 

“In practice, most DNA sequences produce valuable proteins or chemicals that are essentially invisible to the human eye, requiring specialized devices or experiments to observe,” Wilson said. “If the biohackathon were conducted with a standard commercially valuable target, the penetration testing would have taken more than 10 times longer to complete, years instead of months.”

The biohackathon results showed a dramatic reduction in risk. GeneLock reduced the probability of unlocking the genetic asset by random search to about 1 in 85,000 (a 0.001% chance), assuming the unauthorized user had access to the required chemical inputs.

Without access to those inputs, “the likelihood of success by chance becomes effectively negligible,” said Dowan Kim (Georgia Tech PhD 2024), co-lead author of the study.

Commercial Uses and What’s Next 

Although the researchers used a non-commercial fluorescent protein as a test case, the implications extend much further. Many biotechnology companies rely on proprietary engineered strains. New England Biolabs, for example, produces more than 265 non-disclosed enzymes in E. coli, each representing a high-value cell line. 

Protein-based drugs are also manufactured in living cells, and proprietary metabolic pathways are used to produce specialty chemicals, bioplastics, and high-value ingredients. 

“In each case, the genetic blueprint inside the cell represents intellectual property that can be protected by our technology,” said Ishita Kumar, a PhD candidate in ChBE and co-lead author of the study.

While the team’s current focus is on protecting intellectual property in the form of high-value cells, future iterations aim to strengthen biological security more broadly. 

“We are currently developing protection measures to mitigate unauthorized use or release of sensitive cell lines that can be potentially hazardous to human health or the environment,” Wilson said.

“As it stands, GeneLock represents an important shift in biological security, enabling, for the first time, protection of valuable cells at the genetic level, even after physical security measures have been bypassed,” he added. 

The work is already moving toward commercialization. The team filed a provisional patent application with the U.S. Patent and Trademark Office in February 2026 and is forming a company to deploy the technology.

CITATION:

Dowan Kim, Ishita Kumar, Mohamed Hassan, Luisa F. Barraza-Vergara, Christopher A. Voigt, and Corey J. Wilson, “Protecting cells at the genetic level and simulating unauthorized access via a biohackathon,” Science Advances, 2026.

Georgia Tech researchers have created swarms of tiny robotic particles that move and self-organize using only mechanical design — no electronics, software, or sensors. By encoding behavior in each particle’s shape, the team can control how the swarm spreads and reconfigures, with potential applications in medicine and space.

Read more »

It’s uncommon for any startup to receive the Food and Drug Administration’s (FDA) Breakthrough Devices designation. For the roughly 40% of applicants who receive the designation, it shows that the technology has real potential to improve patient outcomes and should get priority attention from the agency. 

The Advanced Technology Development Center (ATDC) in Georgia Tech’s Office of Commercialization announced two of its health technology (HealthTech) portfolio companies, Nephrodite and OrthoPreserve, earned the designation. 

Achieving this rare milestone underscores the caliber of founders, science, and support in ATDC’s 30-company HealthTech portfolio, the incubator’s largest focus area. It’s also a win for Georgia because it reflects the strength of the state’s health innovation ecosystem. 

“This designation is one of the strongest signals the FDA gives that a technology could change the standard of care,” said Greg Jungles, HealthTech catalyst at ATDC. “For ATDC to have two in the same year is remarkable.” 

The Breakthrough Device Program doesn’t waive evidence requirements, but it accelerates learning with the FDA, ATDC’s Jungles said. “That means shorter response times, more frequent meetings, and prioritized review. Teams avoid dead ends and align earlier on study designs and endpoints.” 

For the founders of both startups, their technologies come one step closer to moving their innovations to market. Nephrodite’s technology improves the lives of dialysis patients. OrthoPreserve’s device addresses challenges faced by those who suffer from chronic knee pain. 

Nephrodite: Advancing Continuous Artificial Kidney Technology 

Dr. Nikhil Shah and Dr. Hiep Nguyen, cofounders of Nephrodite, aim to improve care for dialysis patients with end-stage kidney disease who need transplants. These patients often spend three to four hours in a dialysis clinic up to three times a week. Being tethered to stationary machines with needles drawing blood via arm grafts complicates everyday activities — from work tasks to the ability to travel. 

Dialysis addresses chronic kidney disease, which means kidneys no longer work properly. The treatments filter out toxins, waste, and other fluids in the blood. Kidney disease costs Medicare $124.5 billion every year, according to the Centers for Disease Control and Prevention. And those costs are expected to rise because of increasing rates of kidney failure and chronic kidney disease. 

“Dialysis, while lifesaving when it was pioneered in 1952, is incredibly burdensome,” Shah said. Besides being a long process that keeps the patient in a fixed location, it’s physically tiring. “Taking out your blood continually many, many times over, and over the course of four hours is the equivalent of running the Boston Marathon, hitting the finish line, and then someone saying, ‘You're not done; go do it again,’ ” he said. 

A surgeon by training, with expertise in transplantation and oncology, Shah is also an adjunct associate professor in Tech’s School of Interactive Computing. He worked with Nguyen to develop a continuously functioning mechanical artificial kidney, leading to Nephrodite’s formation. 

The FDA’s breakthrough designation on its artificial kidney allows the company to pursue approvals to begin tests in human trials. 

The company traces its beginnings to a German aerospace facility outside Munich, where Nguyen and Shah watched engineers demonstrate a pediatric artificial heart — the Berlin Heart. 

“That’s how we got started,” Shah said. “Seeing an artificial heart that led us to think about doing this for kidneys — because the kidney space has been largely ignored for 70 years.” 

Backed by a German federal grant, Nephrodite grew, moving from Germany to Boston, Massachusetts, then to Austin, Texas, before calling Atlanta home. The company joined ATDC and tapped into other Georgia Tech programs. This included the Center for MedTech Excellence and the Georgia Manufacturing Extension Partnership. Nephrodite also drew on student talent as the researchers quietly worked on their continuous mechanical artificial kidney. 

Nephrodite began interviewing patients to find out what they wanted the artificial kidney needed to solve. 

They learned patients want the ability to be mobile. Patients also desire an alternative therapy to large needles being inserted into arm grafts because the injection sites are prone to infection and the grafts can fail. In addition, the process can be painful and disfiguring. Finally, patients want a quality of life independent of machines. 

“Those quality-of-life needs, especially being free and mobile, were absolutely universal,” Shah said.  

Nephrodite began developing the technology to build its device — a filter surgically implanted in the pelvis area. 

“We developed an implant designed to run constantly, connected to larger blood vessels in the pelvis to avoid arm graft failures, and paired with an external interface that lets patients sleep at night while the system removes toxins and excess fluid,” Shah explained. 

The device also has built-in sensors, with data uploaded to the cloud, enabling medical care teams to remotely monitor their patients while freeing patients from frequent in-clinic visits. 

Shah said Nephrodite’s device could restore everyday independence, while potentially lowering infection risk. 

“It's like having an actual kidney, but without all the issues of an unhealthy one,” Shah said.  

OrthoPreserve: Innovating a Minimally Invasive Meniscus Implant 
 
OrthoPreserve’s technology aims to address issues from people have with their meniscus, the C‑shaped piece of cartilage in a knee joint that acts as a shock absorber between the thigh bone and shin bone. 

Though patients undergo a now-routine surgery to address it, incomplete recoveries are also common. An estimated quarter of patients later experience recurring knee pain. No FDA-approved implant currently exists for this population. Now, OrthoPreserveis developing a minimally invasive, artificial meniscus implant to restore cushioning, relieve pain, and delay — or even prevent — knee replacement for some patients. 

“There are a million meniscus surgeries every year, and 25% of those patients still live with recurring pain,” said Jonathan Schwartz, OrthoPreserve’s founder and CEO. 

Patients can face daily pain from ordinary activities, such as prolonged standing or walking a dog. Other activities like jogging and recreational sports can trigger flares that can lead to swelling and prolonged discomfort, Schwartz said. “Those patients have no reliable options today,” he said. “We’re building a minimally invasive implant to restore cushioning and help people get back to the activities they love.” 

OrhoPreserve’s durable implant restores cushioning, and it could help people return to normal activities and delay invasive knee replacement. Along with this comes potential cost and recovery benefits for the healthcare system.   

Schwartz created the implant as his Georgia Tech master’s thesis in the lab of David Ku in the Lawrence P. Huang Endowed Chair for Engineering Entrepreneurship and Regents' Professor in the George W. Woodruff School of Mechanical Engineering. After industry experience, Schwartz returned to further develop the technology, building on Georgia Tech’s translational expertise 

OrthoPreserve has completed mechanical testing and a successful study. The company is raising a $2 million seed to complete validations and begin human trials, which Schwartz expects to start in 18 months. 

“The FDA breakthrough designation validates that nothing like this technology exists, and that it has the potential to disrupt the standard of care,” Schwartz said, adding the U.S.’ market opportunity is roughly $1.5 billion. “We finally have a minimally invasive option to bridge the gap between meniscus surgery and knee replacement.” 

What FDA Breakthrough Designation Means for ATDC’s HealthTech Startups 

Having a faster and clearer path is a derisking milestone for investors who are evaluating capital intensive medical device technologies, Jungles said. 

“This breakthrough device designation is a really big deal for medical device companies,” Jungles said, adding that startups often fear navigating the FDA approval process. “But this designation adds to the legitimacy of their technologies and the problemsthey are solving. The designation will help them get to market faster, assuming their data continues to meet expectations.” 

ATDC launched its HealthTech vertical in 2018, which is now sponsored by Catalyst by Wellstar ATDC’s HealthTech portfoilo companies include medical devices, biotech, and digital health, among other segments. 

ATDC’s Role in Accelerating HealthTech Innovation 

Nephrodite and OrthoPreserve’s founders noted ATDC’s coaching and programming as critical in navigating fundraising and regulatory milestones. Another factor, they said, was ATDC’s connection to Georgia Tech’s labs and facilities and prototyping support and clinical advisors from across metro Atlanta.  

“We meet with ATDC coaches every two to four weeks to troubleshoot and plan,” Schwartz said. “Having that level of seasoned guidance, all without consultant-level costs, has been huge.” 

Jungles added that two Breakthrough device designations in the same year reflects ATDC’s selection rigor, noting he’s evaluated hundreds of technologies since the HealthTech vertical launched. 

“It reflects the caliber of the companies in ATDC, specifically in the medical device space,” Jungles said. “It’s the strength of their teams, the persistence of the founders, and the collaboration of the ecosystem in Georgia and Atlanta.” 

 

At any given time, only 5% of patents filed worldwide ever get licensed, and 90% of startups fail, according to industry and U.S. Bureau of Labor statistics.

An innovative program in Georgia Tech’s Office of Commercialization believes that assessing the commercialization potential of new inventions earlier could improve their likelihood of success in transitioning from the research lab to the commercial market.

Now in its third cohort, the Entrepreneurship Assistants Program (EAP) pairs a Scheller College of Business MBA student with a student or faculty researcher behind the invention. The students leverage a suite of market analysis tools to assess its market potential.

“Our goal is to simplify the process of advancing an invention to commercialization, whether through licensing or attracting funding to establish a startup,” says Paul Joseph, a former principal research scientist at Georgia Tech’s Institute for Electronics and Nanotechnology who joined the Office of Commercialization in 2023. In this new role as principal, he developed the EAP in the Office’s newest unit, Quadrant-i. 

Early-Stage Assessments

Georgia Tech’s program focuses on early-stage assessment of an invention’s market potential.

“This is about de-risking the technology — to help researchers understand what’s required to develop a minimum viable product to push the technology readiness level up to attract funding or investments,” says Joseph.

One technology assessed by EAP recently received a $50,000 Georgia Research Alliance grant.

Jonathan Goldman, Quadrant-i’s director, hopes the program will help inspire Georgia Tech research faculty to embrace entrepreneurship more broadly. 

“Georgia Tech President Ángel Cabrera set the goal to triple the number of startups between 2019 and 2029 soon after he was appointed,” recalls Goldman, noting that the program could accelerate that effort while reversing a national trend of university licensing offices losing money while helping researchers pursue startups. 

Georgia Tech is no stranger to supporting commercialization efforts with research. The EAP was derived from the National Science Foundation's Innovation Corps (I-Corps) program, which trains researchers and their entrepreneurial leads to do customer discovery of their innovations to develop a go/no go decision around launching a business. Goldman served as a mentor for several Georgia Tech i-Corps teams between 2015 and 2020. 

Market Viability of New Innovations

Today’s EAP has attracted enthusiastic participation from Scheller College students in the Technology Innovation: Generating Economic Results (TI:GER®) program, which integrates classroom instruction and technology-innovation projects into practical, real-world experiences. 

Lithium-Ion Battery Recycling

One TI:GER participant, Analisa Wade, a former digital transformation consultant,  participated in two EAP assessments, including one during the pilot program, where she evaluated a novel approach to recycling lithium-ion batteries used to power electric cars. Handling the batteries is both costly and dangerous due to their tendency to ignite. Recycling the batteries currently costs more than mining the raw materials. 

“I knew nothing about lithium-ion batteries. This program allowed me to dive deep and speak with people who could help me understand how the technology has evolved.”

Wade worked with a master’s chemistry student from a faculty inventor’s lab, and both attended a conference in Detroit focused on lithium-ion battery advances to conduct customer discovery interviews and validate the value proposition of this new battery recycling technology. 

“The experience was extremely valuable, especially as a previous entrepreneur. I had experience running a business, but this gave me another way of looking at it, especially from a technological commercialization standpoint,” says Wade, who will work for Microsoft after she completes her MBA in the spring.

To date, the EAP has assessed 21 breakthroughs, and the comprehensive assessment report generated by the students helped inform proposals to support commercialization.

For the licensing associates in the Office of Commercialization, the reports are “highly detailed, realistic, and thorough,” says senior licensing associate Michael Varon. “The students invested a lot of time and energy identifying partners and potential problems. I prefer this type of assessment report over the report we get from an external assessment firm.”

Mary Albertson, director of the Office of Technology Licensing, says the deliverables provided to her team, including a comprehensive report and a summary video, “have become the cornerstone of our marketing efforts.”

She adds, “Our mission is to move Georgia Tech discoveries from the benchtop to the public and make a positive impact. Communicating the stage and value of the technology to industry partners is a critical step.” 

Efficient Satellite Propulsion

William Trenton Gantt, a U.S. Army veteran and engineer enrolled in the TI:GER program, analyzed a Georgia Tech propellant management device that would enable satellite platforms to utilize a one-tank system instead of a two-tank system, allowing for more revenue-generating payloads. His research included customer discovery interviews with smallsat manufacturers such as Kuiper and Starfish Space, as well as SoloPulse, a radar detection company in Atlanta.

“We talked with them about their challenges with mission endurance and what kind of systems their satellite buses use,” recalls Gantt, who is in the final semester of his MBA studies and will be working for Collins Aerospace. “For cubesats, we’re seeing a lot more hybrid systems based on the use case of the satellite customers. These customers are using hybrid propulsion systems, both gas and electric, to maximize the lifespan of their cubesat assets and create as much value from them as possible. It’s much more attractive for these satellite bus manufacturers to take on less equipment, so having a reduction in a fuel tank like our technology is something that’s a big market need right now.”

Brine-Free Water Desalination

Another Georgia Tech innovation evaluated a water desalination technique called salinity exchange electrodialysis, a process that uses selective ion exchange membranes to separate seawater and wastewater and can produce high-quality desalinated water at a lower energy cost than conventional methods. 

According to Rakesh Shankar, a master’s student in the George W. Woodruff School of Mechanical Engineering, “The technology is energy- and cost-efficient,” using only one kilowatt of energy. It does not produce brine, a byproduct of wastewater that contains a high salt concentration, making it environmentally unfriendly.

Pascaline Ezouah, an Evening MBA student set to graduate from Scheller College in the spring, led the market analysis effort. 

“When looking at the technology, we identified potential customer segments that would benefit — namely, power plants, desalination plants, and data centers,” she says. “The value proposition for each market is different, but the overall recommendation to the researchers was to license the technology.”

The project hit home for Ezouah, a Ghana native born in one of the most water-stressed regions in the world. 

“Desalination is a really big thing — right now Ghana is having issues with fresh water because of over-mining.”

Scaling the Program  

Scheller College plans to offer the EAP as a three-credit course beginning this summer. The class, Technology Commercialization Practicum, will help scale the program more quickly across the Institute while also supporting Georgia Tech’s commitment to interdisciplinary collaboration.

Jonathan Giuliano, professor of the practice and executive director and academic director of TI:GER, says EAP students requested that the course be created since it could serve as “the perfect capstone to their TI:GER experience.”

It’s a win-win for both researchers and students, he added. “For researchers, the students’ market, industry, and strategy analysis can inform both research grant proposals and startup funding. The benefit to students is that they further develop their skills in how to turn inventions into innovations — an important and a rare skill set not only in early-stage ventures but also in corporate innovation.”

About Georgia Tech Office of Commercialization

Georgia Tech Commercialization is a cornerstone in transitioning the Institute's leading-edge research into real-world applications. It encompasses four pivotal units: CREATE-X, VentureLab, Quadrant-i, and Technology Licensing. These units empower students and faculty to launch startups, provide comprehensive commercialization support, manage intellectual property, and facilitate the transformation of research into viable businesses. Our mission is to provide world-class commercialization services, catalyzing research and innovation to improve the human condition and solidify Georgia Tech's position as a leader in technology and entrepreneurial impact.

For Anatoly Shilman, one of the biggest risks in building a startup occurs before a product is ever launched. It happens during early customer discovery, when founders rely on surveys, interviews, and research questions to validate an idea, often without realizing those questions may be shaped by cognitive bias — an unconscious mental shortcut that can lead to inaccurate thinking or decision-making.

After years of working as a serial entrepreneur and startup mentor, Shilman noticed a recurring issue: teams spending months building products based on feedback that was unintentionally influenced by the way questions were framed.

“Very few products fail because the technology doesn’t work,” said Shilman. “They fail because there was no market need. Often, that traces back to early research where founders heard what they expected to hear, rather than what the market was actually saying.”

That observation led Shilman and his team to create CogBias AI, a decision-intelligence startup developing tools to identify cognitive bias in written communication used for research, surveys, and customer discovery.

Turning Behavioral Science Into a Practical Tool

CogBias AI focuses on the earliest inputs that shape decisions: the questions themselves. The platform analyzes written prompts, such as survey questions or research language, to identify patterns associated with cognitive bias and suggest alternative phrasing aligned with the user’s intent.

During early testing, the team analyzed customer feedback surveys from large organizations and found that a significant portion of commonly used questions did not produce actionable insights because they were leading, ambiguous, or misaligned with the decision being made. In those cases, revising the questions changed the clarity and usefulness of responses.

According to Shilman, the platform is designed to reduce the time teams spend rewriting and reworking questions before sending them out, while improving confidence that the responses they receive reflect what respondents actually mean — stripping out the bias.

“Bias is often invisible, which is what makes it hard to catch,” he said. “The goal is to help teams see where judgment may be influencing outcomes before decisions are locked in.”

The approach draws from behavioral science and decision theory and is being developed using expert-informed models rather than relying solely on general-purpose AI outputs. The company is currently refining the platform based on early use cases rather than formal customer case studies.

The Role of the ATDC Ecosystem

CogBias AI began scaling with the Advanced Technology Development Center (ATDC), Georgia Tech’s statewide startup accelerator. Shilman, who previously served as a mentor with Georgia Tech’s former Flashpoint accelerator, said ATDC provided a structured environment to develop a complex idea that does not fit neatly into existing markets.

“ATDC gave us the space to test assumptions, pressure-test decisions, and work through uncertainty without rushing to force the product into a traditional mold,” he said.

The accelerator supports founders from across Georgia, including companies that are not based on licensed Georgia Tech intellectual property. For CogBias AI, participation in the ATDC community has provided access to coaching, peer feedback, and operational support during a stage when the company is still refining both its technology and positioning.

Looking Ahead

CogBias AI is preparing for its first formal press announcement while continuing to develop the platform ahead of a broader commercial release. Shilman said the focus remains on building a responsible tool that improves how organizations gather and interpret information before making high-stakes decisions.

Through ATDC and Georgia Tech’s broader entrepreneurship ecosystem, founder-led startups like CogBias AI illustrate how early-stage ideas can be supported as they move from observation to application, even before they are fully in market.

 

Hospital stays can be long and arduous; they can also cause serious complications. When a person lies in one position too long and begins to sweat, painful sores called pressure injuries (PIs) can form on the body, leading to infection or even death. A patient can develop a PI in a few days — or even a few hours. And once present, a PI is hard to treat. To address this issue, researchers at Georgia Tech have developed a new, flexible, sensor-filled fabric to monitor areas at risk of PIs and alert hospital staff when a patient needs to be turned.

Read more about Georgia Tech’s research on preventing pressure injuries »

Georgia Tech researcher Nick Housley is developing a drug‑delivery system designed to send cancer treatments directly to tumors while minimizing damage to healthy tissue. His team’s approach uses self‑assembling nanohydrogels (SANGs) that circulate through the body, remain inactive in healthy environments, and release their drug payload only when they encounter the unique chemical conditions created by tumors. This “cancer‑agnostic” strategy avoids the pitfalls of traditional targeted therapies, which can lose effectiveness as tumors evolve, and aims to reduce the harsh side effects patients often endure. Early preclinical results show that the nanohydrogels successfully concentrated drugs at tumor sites, and Housley’s team is now preparing for broader testing to move the technology toward clinical trials.

Read more »

Alison Sizer started as someone who loved innovation and problem-solving. For 14 years, she worked at Apple and Nike, where she learned how to blend innovation with customer insight: how to spot patterns, translate problems into opportunities, and turn ideas into strategies for growth. 

Applying what she’d learned along the way, Sizer started Growth Impact to support startups and stakeholders in the innovation ecosystem. As a part of her business, she created partnerships and networks between the U.S. and South Africa, bridging the gap between startups and corporations to encourage co-creation and pilot projects. During this time, she saw how much early‑stage founders needed clear frameworks, honest guidance, and hands‑on support. 

“I started Growth Impact to support startups and stakeholders such as venture studios, investors, and accelerators. I support early-stage startups in finding product-market fit, customer understanding, go-to-market strategy, and business model development,” she said. “I also help startups with fundraising readiness and enterprise readiness. I support stakeholders by helping to assess viability, and de-risk new ventures, as well as connecting startups to enterprises.” 

Eventually, her work brought her in contact with Georgia Tech. She was working with a South African innovation lab to enable pilot projects between startups and enterprises with the goal of facilitating the co-creation of digital solutions, which led her to Rahul Saxena, director of CREATE-X. 

Sizer said she reached out to see if any potential CREATE-X startups or enterprises would want to connect to the companies she was working with in South Africa.

“Over the last few years, there's been quite a lot of interest in Georgia Tech and Atlanta in terms of a tech and innovation hub in the U.S., and there's a lot of investment happening too, in both the city of Atlanta and in Georgia Tech, in entrepreneurship and innovation and technology,” she said. “I think it's an interesting market.”

Once connected, she kept meeting Georgia Tech founders, many from CREATE‑X.

Quietly, she began helping where she could, making introductions for CREATE-X founders outside of Atlanta. For Augment Health, she made investor and potential partner introductions. For the founder of Strapt, she made introductions to investors, shared market insight, and highlighted the company in her own newsletter, which has an audience of innovation ecosystem stakeholders, including more investors. And for ZenVR, she made a connection to WeFunder for funding, which resulted in $250,000 raised.  

Collaborating with CREATE-X on a webinar, Sizer also taught Startup Launch alumni about customer understanding and segmentation, value proposition, and other topics for health and wellness founders. Beyond connecting, Sizer shaped mindsets. 

In her business, one founder she worked with was building non‑toxic performance apparel for women — a product selling through Amazon, REI, and even the U.S. military. The founder had ambition but struggled to balance DTC (direct to consumer) sales, retail, and B2B opportunities. Sizer helped her analyze her data, identify her real early adopters, and rebuild her value proposition and messaging. With a clearer customer understanding and stronger brand direction, the founder revamped her website and refined her pitch.

“I love that thrill of them being excited about implementing some of the ideas and things we talk about, seeing the growth in their business, and the positive change in their business. That really excites me,” she said.

Atlanta is an enterprise-heavy city with Fortune 500 companies, SaaS (Software as a Service) companies, and a growing biotech sector. The startup ecosystem is growing in Atlanta, and with that comes advantages. 

“I have noticed that there's a lot of strong support for Atlanta and Georgia entrepreneurs from other Atlanta and Georgia entrepreneurs,” she said. “They all support each other.”

Over the years, Sizer has advised or mentored over 100 startups and built investor connections.  

“My business is Growth Impact, because growth and impact are part of my core values. I'm glad to give back and support early entrepreneurs, sharing knowledge, tools, and resources,” she said.

As a founder, Sizer went through her own learning curve. When she first launched her company, she assumed her target customers would be venture capital firms and spent months talking to pre‑seed and seed investors, only to discover that VCs either didn’t fund the kind of operational support she offered or they expected founders to pay for it themselves. Meanwhile, the founders she spoke with said they needed her help but didn’t have the budget. She said it was a classic chicken‑and‑egg problem.

“I said, OK, this is not my target customer. The target customer is the startup,” she said. “That's where the pivot point was for me.”
That shift reshaped her entire business and reinforced the same advice she now gives students: Talk to customers, listen deeply, and don’t be afraid to adjust when the data points you in a new direction.

She officially joined the CREATE‑X mentor community last year to help more founders, guiding them in finding product-market fit, and understanding who needs this solution and why.

One thing Sizer emphasized, however, is the need for founders to continue to take initiative and be resilient in the face of challenges.
“A mentor can guide you or ask the right questions, but the founder has to find the path,” she said.

Ready to build something real?

Meet mentors like Alison Sizer in Startup Launch, where you can develop a startup to solve real-world problems and build entrepreneurial skills. Apply to Startup Launch today; applications close Tuesday, March 17.
Interested in mentoring?

Want to mentor and support the next generation of Georgia Tech founders?

Fill out our engagement form to join CREATE‑X’s mentor network. 

The Georgia Institute of Technology has been awarded up to $21.8 million from the Advanced Research Projects Agency for Health (ARPA-H) to deliver a first-of-its-kind therapy to patients with lymphatic disease.

For many of these patients, care has long meant pain and disfigurement alongside other severe side effects, rather than receiving treatment that addresses the disease itself. This new ARPA-H award marks a potential turning point.

Lead researcher Susan Napier Thomas, Woodruff Professor in the George W. Woodruff School of Mechanical Engineering and the Parker H. Petit Institute of Bioengineering and Bioscience (IBB), has collaborated with her colleague J. Brandon Dixon, Woodruff Professor in the Woodruff School and IBB, for more than a decade on this project. The research partners are driven by the lack of meaningful treatment options available to patients.

“Funding support at this level is unprecedented,” Thomas said. “It finally gives us a chance to move beyond symptom management and toward real treatment. We’re addressing an underserved population with a huge unmet need.” 

A Gap in Care

The lymphatic system helps keep fluid moving through the body and plays a key role in immune health. When it does not function properly, fluid can build up in tissues, causing chronic pain and other long-term complications. Thomas noted that despite its toll on patients, lymphatic disease has lagged decades behind cardiovascular care in both treatment and research investment. 

“We are excited about this groundbreaking project in lymphatic engineering,” said Andrés García, IBB executive director. “By uniting interdisciplinary expertise, this work addresses long-standing challenges in lymphatic disease and moves meaningful solutions closer to the patients who need them most.”

What Comes Next

In the coming years, Thomas, Dixon, and their research partners will work toward an initial human trial, with an early focus on rare lymphatic conditions in children, as well as chronic disease in adults.

“This award reflects Georgia Tech’s growing leadership in using engineering to solve some of healthcare’s biggest challenges,” said Carolyn Seepersad, Eugene C. Gwaltney Jr. School Chair and professor in the Woodruff School. “It reinforces the Institute’s role in advancing innovations that improve patient care and strengthen Georgia’s position as a hub for health technology and biomedical innovation.”

The award was made through ARPA-H’s Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program led by Dr. Kimberley Steele.

This research was funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H) under Agreement No. 1AY2AX000137-01. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. government.

 

 

 

Georgia Tech’s faculty startup engine Quadrant-i, together with the Space Research Institute (SRI), launched the first cohort of the CreationsVC Space Fellows Program. Funded by space technology venture capital firm CreationsVC, the program enables faculty to explore promising early-stage innovations and their potential for future commercial impact. 

“This first set of CreationsVC Fellows offers an exciting cross-section of innovative hardware and software technologies built on Georgia Tech’s legacy of space exploration, hardware development, and product commercialization,” said Jud Ready, SRI executive director. 

In the first year of the three-year program, CreationsVC provides $125,000 to promote and accelerate innovations that have both space and terrestrial applications. The series offers participants training focused on customer discovery, engaging and compelling storytelling, value proposition design and quantification, and lean/agile project/product management.

“CreationsVC is centered on a deep appreciation for innovation and big thinking,” said Steve Braverman, co-founder and managing partner of CreationsVC. “We felt this was the right time to align our efforts in sourcing and supporting dual-value technologies that will have an impact on both Earth and space.” 

The six startups tackle real-world space research problems like supply chain management, how artificial intelligence works in space, and navigation.

“We are excited CreationsVC is providing us with an opportunity to try new approaches to accelerate deep tech development,” said Jonathan Goldman, Quadrant-i’s director. “These are the toughest kinds of startups to build, and we look forward to the learning we will gain from forcing our innovators out of their comfort zones to embrace some new and valuable skills.”

Meet the cohort:
 

Company: CIMTech.ai
 

Founders: Shimeng Yu, James Read

School: School of Electrical and Computer Engineering (ECE)

Objective: To develop energy-efficient, radiation-tolerant artificial intelligence processors using a persistent type of ferroelectric memory. The startup aims to improve applications requiring high power efficiency, such as battery-powered devices and space-based systems.

Why Q-i: “The advantage of Q-i is in helping technical founders turn their research into products that solve customers’ problems,” noted James Read. “For us, that means talking with potential customers and hearing their pain points directly from the source. Now we’re use that information to build a convincing narrative around our startup’s value for stakeholders and investors.” 

Company: SkyCT
 

Founders: Morris Cohen, Matthew Strong

School: ECE

Objective: To provide up-to-date mapping of the electrical properties of the upper atmosphere, with applications to GPS-free navigation, long-range communication, and satellite and launch vehicle viability. The startup uses the radio energy released by lightning strikes to create this map. 

Why Q-i: “This weird region about 50 miles up from Earth’s surface is both really hard to track and measure, and also impacts a surprising array of applications,” said Cohen. “It’s sometimes called the `ignorosphere’ because of how difficult it is to measure, and it’s time we change that.” 

Company: Penumbra Autonomy
 

Founders: Panagiotis Tsiotras, Juan Diego Florez-Castillo, Iason Velentzas 

School: Daniel Guggenheim School of Aerospace Engineering (AE)

Objective: To commercialize algorithms that help spacecraft maneuver when they have limited information on their environment. The algorithms use state-of-the-art computer vision and localization techniques. This could benefit manufacturing, assembly, and refueling in orbit, as well as enable monitoring, situational awareness, and debris removal. 

Why Q-i: “The program offers a conduit to entrepreneurship opportunities and spinoff companies in the space domain by providing guidance and commercialization ‘know-how,’” said Panagiotis Tsiotras. 

Company: TerraMorph

 
Founders: Yashwanth Kumar Nakka, Sadhana Kumar, Vincent Griffo, Sachin Kelkar

School: AE

Objective: To create an autonomous rover platform with adaptive, reconfigurable mobility. The rover will implement software and sensing algorithms to automatically detect terrain type and improve traction and energy usage. This could be used on the moon or Mars, or even terrestrial search and rescue. 

Why Q-i: “TerraMorph was developed to address fundamental challenges in mobility and autonomy across uncertain terrain,  but successfully translating that work into impact requires creative guidance, critical feedback, and experienced perspectives beyond the lab,” said Yashwanth Kumar Nakka. “Q-i’s culture of leading by example and fostering strong, ethical teams aligns closely with how we want to build TerraMorph: iteratively, thoughtfully, and with a focus on real-world deployment.” 

Company: OpenWerks
 

Founders:  Shreyes Melkote, Mike Yan

School: George W. Woodruff School of Mechanical Engineering

Objective: To deliver real-time manufacturing supply chain visibility for the space and national security industries. OpenWerks technology aims to dramatically reduce current sourcing cycles from eight months down to weeks by connecting corporate buyers directly with verified supplier manufacturing capability and capacity data. 

Why Q-i: “From the very beginning, principals at VentureLab and  Q-i offered a clear pathway to translate academic research into a viable business,” said Mike Yan. “Their reputation for guiding Georgia Tech startups through both business and technology derisking, combined with their comprehensive ecosystem of programs and coaches, made them the natural partner for our entrepreneurial journey.”

Company: 8Seven8
 

Founders: Chandra Raman

School: School of Physics

Objective: To manufacture quantum hardware in Georgia. 8Seven8 aims to put high-precision atomic clocks and gyroscopes on a chip for applications ranging from aircraft navigation to industrial automation.  

Why Q-i: “They have mentored me and my students through the commercialization process, providing opportunities such as the Space Fellows Cohort,” Chandra Raman said. “One of my former students, Alexandra Crawford, gained valuable business experience through a Q-i entrepreneur’s assistantship, and is now working at 8Seven8 full-time. They have also guided me through the process of obtaining funding through the Georgia Research Alliance for our commercialization effort.”